Jul 2, 2026 01:05PM
Jul 2, 2026 09:00AM
Jun 25, 2026 08:33AM
Jun 25, 2026 08:32AM
Jun 22, 2026 09:06AM
Jun 22, 2026 09:06AM
Jun 3, 2026 12:05PM CEO Statement to Shareholders
May 27, 2026 09:06AM
May 27, 2026 09:06AM
May 12, 2026 09:17AM
May 12, 2026 09:16AM
May 5, 2026 01:05PM
Apr 30, 2026 09:15AM
Apr 29, 2026 09:50AM OSR Holdings signs $815 million license deal for VXM01 drug candidate
Apr 29, 2026 09:50AM
Apr 9, 2026 09:16AM
Apr 9, 2026 09:15AM
Mar 30, 2026 09:00AM
Mar 27, 2026 09:00AM
Mar 23, 2026 08:40AM
Mar 23, 2026 08:30AM OSR Holdings Updates $815 Million VXM01 Licensing Deal Structure to Capture Value at Parent Level
Mar 19, 2026 09:45AM
Mar 19, 2026 08:55AM
Mar 5, 2026 09:31AM
Mar 5, 2026 09:30AM
Feb 2, 2026 09:57AM
Feb 2, 2026 09:50AM
Jan 27, 2026 08:32AM OSR Holdings completes Woori IO acquisition, reviews device unit merger
Jan 27, 2026 08:30AM
Jan 16, 2026 09:24AM
Jan 14, 2026 09:29AM
Dec 19, 2025 11:51AM
Dec 4, 2025 03:19PM
Nov 21, 2025 09:20AM
Oct 20, 2025 11:40AM Emerging Growth Research Initiates Coverage on OSR Holdings, Inc. with a Buy-Emerging Rating and $10.00 Price Target
Jul 31, 2025 12:46PM
Jul 30, 2025 04:11PM
Jul 15, 2025 07:30AM
Jul 9, 2025 07:59AM
Jul 8, 2025 10:04AM
Apr 3, 2025 07:31AM
Mar 26, 2025 07:19AM OSR Holdings' (OSRH) Vaximm AG Announces Results from Phase 2a Trial of VXM01 and Avelumab Combination Therapy in Glioblastoma
Mar 25, 2025 07:02AM

423,324 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All